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Summary
Background: Syndecan-4 is a transmembrane heparan sulfate-carrying glycoprotein that medi-
ates signal transduction pathways activated by growth factors and cell surface receptors,
thereby modulating tissue regeneration, angiogenesis, and focal adhesion. The aim of the
present study was to determine the clinical use of serum syndecan-4 concentration for diagnosis
of heart failure.
Methods: Concentration of serum syndecan-4 and other biomarkers of heart failure was mea-
sured in 45 patients with heart failure and 21 healthy subjects. Clinical and echocardiographic
parameters of cardiac function were recorded.
Results: Serum syndecan-4 concentration signiﬁcantly increased in proportion to the decrease
in ejection fraction (r =−0.599, p < 0.001) and increase in the left ventricular (LV) mass index
(r = 0.315, p < 0.05). Serum syndecan-4 concentration was signiﬁcantly correlated with LV geo-
metrical parameters (i.e. LV mass index, LV end-diastolic volume, and LV dimension), while
B-type natriuretic peptide (BNP) was signiﬁcantly correlated with pressure-related parame-
ters [i.e. early transmitral ﬂow velocity/early diastolic velocity of the mitral valve annulus
(E/e′), right ventricular systolic pressure, and left atrial volume index]. Syndecan-4 concen-
tration did not signiﬁcantly correlate with plasma BNP, transforming growth factor-1, matrix
metalloproteinase-2, and tenascin-C concentrations. Serum syndecan-4 concentration could
predict cardiac death and re-hospitalization due to heart failure (area under curve, 0.706,
p < 0.05).
∗ Corresponding author. Tel.: +81 27 220 8142; fax: +81 27 220 8158.
E-mail address: araim@showa.gunma-u.ac.jp (M. Arai).
0914-5087/$ — see front matter © 2011 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Conclusion: Serum syndecan-4 concentration shows promise as a novel diagnostic and prognostic
biomarker for heart failure. Since syndecan-4 correlated with LV geometrical rather than hemo-
dynamic parameters, serum syndecan-4 may represent a biomarker of LV remodeling in the failing
ardi
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blood. Plasma BNP concentration was measured with an
immunoradiometric assay (Shionoria BNP assay, Shionogiheart.
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hronic heart failure results from myocardial degradation
nd pathologic structural regeneration in a process known
s cardiac remodeling. This multistage and multicellular
epair process is mediated by a complex interplay between
rowth factors and cytokines. Progressive and end-stage
eart failure is a culmination of this pathologic process.
any biomarkers have been proposed to diagnose heart fail-
re and predict prognosis of the patient. However, the type
f cardiac function that each biomarker represents remains
ncertain.
Various studies have demonstrated that extracellular
atrix (ECM) components, namely proteoglycans and ﬁbrous
roteins such as collagen, play an essential role in car-
iac remodeling. Although the role of collagen in cardiac
ypertrophy and heart failure has already been well char-
cterized, comparatively little is known about the role of
roteoglycans. Proteoglycans bind to long-chain polysac-
haride glucosaminoglycans on the cell surface, and those
onsisting of transmembrane core proteins carrying heparan
nd chondroitin sulfate are called syndecans. Syndecans
re thought to mediate cardiac remodeling by transmit-
ing the cellular actions of a number of growth factors,
ncluding ﬁbroblast growth factor, vascular endothelial
rowth factor, and transforming growth factor-beta (TGF-)
1,2].
Syndecan-4 (ryudocan) is the most extensively studied
soform of the syndecan family. Syndecan-4 knockout mice
how delayed wound repair and impaired angiogenesis [3]. In
he skeletal muscle of syndecan-4 knockout mice, satellite
ells cannot reconstitute damaged cells and cannot pro-
iferate and differentiate into myotubes, suggesting that
yndecan-4 also participates in muscle development and
egeneration [4]. Furthermore, the plasma syndecan-4 level
s elevated in patients with acute myocardial infarction with
peak at 2 weeks after infarction [5].
Although syndecan-4 plays a signiﬁcant role in the car-
iovascular system, the role of syndecan-4 in heart failure
emains unclear. Thus, the present study investigated the
linical use of serum syndecan-4 concentration as a rep-
esentative component of ECM in the diagnosis of heart
ailure. The aims of the study were: (1) to determine which
chocardiographic parameters are represented by serum
yndecan-4 concentration; (2) to determine whether serum
yndecan-4 concentration predicts prognosis of patients
ith heart failure; and (3) to determine the difference
etween syndecan-4 as a potential biomarker for heart fail-
re and those currently being used [i.e. B-type natriuretic
eptide (BNP), TGF-1, matrix metalloproteinase-2 (MMP2),
nd tenascin-C]. At present, BNP is considered the most
owerful predictor of cardiac death and re-hospitalization
or heart failure. TGF-1 and MMP2 regulate ECM turnover,
nd tenascin-C is another proteoglycan that reportedly
ncreases in the failing heart [6].
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aterials and methods
atients
local ethics committee and internal review board
pproved this study. All protocols conformed to the ethi-
al guidelines of the 1975 Declaration of Helsinki. Written
nformed consent was obtained from all patients.
This study enrolled 45 Japanese patients with chronic
eart failure (31 men and 14 women), age 30—97 years
mean age 64.8± 15.9 years), who were admitted to Gunma
niversity Hospital, Tomioka General Hospital, and Tsuru-
aya Hospital between June 2006 and February 2007 for
he treatment of heart failure, in addition to 21 healthy
ubjects (12 men and 9 women, and age 25—81 with mean
ge 49.2± 12.5 years). The main demographic and clinical
haracteristics of the patients are summarized in Table 1.
he prevalence of idiopathic dilated cardiomyopathy, hyper-
rophic cardiomyopathy, ischemic cardiomyopathy, and
ypertensive cardiomyopathy was 22%, 13%, 20%, and 44%,
espectively. The present study excluded patients with
history of neoplastic, hepatic, infectious, collagen, or
eripheral atherosclerotic diseases or patients who under-
ent any surgical procedure in the preceding 6 months.
one of the patients had signs of infection and collagen
isease at the time of evaluation.
Patients were followed for 3 years and their clinical
utcomes were recorded. The endpoint of follow-up was
eﬁned as cardiac death or re-hospitalization due to heart
ailure. Cardiac death during the re-hospitalization was
ounted as single event. Additionally, second or more re-
ospitalizations were not counted as additional events but
ingle event at the time of ﬁrst re-hospitalization.
lood sampling and measurement of syndecan-4
lasma and serum samples were obtained from peripheral
enous blood. Whole blood was withdrawn from an ante-
ubital vein, placed in tubes containing sodium EDTA, and
ept on ice. The plasma was separated by centrifugation
or 30min, and plasma and serum samples were stored
t −80 ◦C until analysis. Serum syndecan-4 concentrations
ere measured by sandwich enzyme-linked immunosorbent
ssay (ELISA) according to the manufacturer’s protocol (IBL
o., Ltd., Fujioka, Japan). This ELISA system recognizes
he secreted ectodomain of the syndecan-4 molecule inharmaceutical Co., Osaka, Japan). Plasma TGF-1 concen-
ration (R&D Systems, Minneapolis, MN, USA), serum MMP2
ctivity (GE Health Care Japan, Tokyo, Japan), and serum
enascin-C concentration (IBL Co., Ltd.) were measured by
LISA.
Serum syndecan-4 level in heart failure
Table 1 Baseline characteristics of patients.
Mean± standard
deviation or number
of patients (% of
patient population)
Age (years) 64.8± 15.9
Gender (male) 31 (69)
Hypertension 26 (58)
CHF admission in previous year 29 (64)
Etiology
Dilated cardiomyopathy 10 (22)
Hypertrophic cardiomyopathy 6 (13)
Ischemic cardiomyopathy 9 (20)
Hypertensive cardiomyopathy 20 (44)
Medication
-Blocker 19 (42)
ARB and/or ACEI 36 (80)
Spironolactone 8 (18)
Loop diuretics 29 (64)
NYHA class
I 16 (36)
II 18 (40)
III 5 (11)
IV 6 (13)
Plasma polypeptide hormones
Plasma BNP (pg/mL) 509.7± 454.3
Echocardiogram
LV end-diastolic dimension (mm) 53.6± 10.8
LV end-systolic dimension (mm) 41.5± 14.8
LV end-diastolic volume (mL) 109.7± 51.5
LV end-systolic volume (mL) 56.6± 44.3
EF (%) 48.4± 17.5
LV mass index (g/m2) 142.9± 40.2
E/e′ 13.9± 5.1
LA volume index (mL/m2) 40.9± 15.8
ARB, angiotensin receptor blocker; ACEI, angiotensin-converting
enzyme inhibitor; BNP, B-type natriuretic peptide; CHF, chronic
heart failure; EF, ejection fraction; E/e′, early transmitral ﬂow
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NYHA, New York Heart Association; LV, left ventricle; LA, left
atrium.
Echocardiographic measurements
Two-dimensional imaging was performed according to the
recommendations of the American Society of Echocardiogra-
phy [7]. Pulsed Doppler was used to record transmitral ﬂow
in the apical four-chamber view [8]. Tissue Doppler veloc-
ities were acquired at the septal and lateral annular sites
and averaged as previously described [9]. These measure-
ments were performed using Aplio echocardiograph (Toshiba
Medical Systems Co., Ltd., Tochigi, Japan). Studies were
analyzed by an echocardiologist blinded to all clinical data.Statistical analysis
Values are expressed as the mean± standard deviation.
Statistical analysis was performed using SPSS version 17.0
(SPSS Inc., Chicago, IL, USA). Serum syndecan-4 concentra-
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ion of normal subjects and patients with heart failure was
ompared using Mann—Whitney test. Multiple and simple
egression analyses were applied to determine the cor-
elation among serum syndecan-4 concentration, clinical
tatus, echocardiographic parameters, and other biomark-
rs associated with heart failure. Data of biomarkers were
onverted by logarithmic transformation and then statisti-
al tests were performed. The optimal serum syndecan-4
oncentration was evaluated by receiver operating charac-
eristic (ROC) curve. The clinical outcomes were displayed
ith Kaplan—Meier event-free curve and compared with the
se of log-rank test. A probability value <0.05 was consid-
red statistically signiﬁcant.
esults
linical characteristics and serum syndecan-4
oncentration
linical characteristics of patients with heart failure are
ummarized in Table 1. Of the 45 patients with heart fail-
re, 64% had a previous history of overt heart failure within
he past year. The highest incidence of functional status
ased on the New York Heart Association (NYHA) classiﬁ-
ation was found for class II (40%), followed by classes I
36%), III (13%), and IV (11%). The mean left ventricular
LV) ejection fraction (EF) (48.4± 17.5%) was lower than
hat of healthy subjects (72.0± 5.3%, p < 0.05) and the LV
ass index (142.9± 40.2 g/m2) of patients with heart fail-
re was signiﬁcantly higher than that of healthy subjects
87.3± 9.2 g/m2, p < 0.05).
Since the distribution pattern of serum biomarker con-
entration did not match with normal distribution, data
ere converted by logarithmic transformation and then sta-
istical tests were performed. Themean plasma BNP concen-
ration of patients with heart failure (509.7± 454.3 pg/mL)
as signiﬁcantly higher than that of healthy subjects
4.0± 2.7 pg/mL, p < 0.05). Similarly, serum syndecan-4 con-
entration was signiﬁcantly higher in patients with heart
ailure than in healthy subjects (22.5± 12.3 ng/mL vs.
.7± 3.3 ng/mL, p < 0.01; Fig. 1). Although healthy subjects
ere younger than patients, serum syndecan-4 concen-
ration was not signiﬁcantly different among different
ges in healthy subjects (correlation coefﬁcient of serum
yndecan-4 concentration and age, 0.171; ns), suggesting
hat difference in serum syndecan-4 concentration between
atients and healthy subjects is not due to age difference.
elationship between serum level of biomarkers
nd echocardiographic parameters
e next determined which biomarkers represent the
chocardiographic functional and architectural parameters.
able 2 shows the multiple correlation coefﬁcient (R) of the
redictive equation for each echocardiographic parameter
nd the partial regression coefﬁcient (ˇ) of each biomarker
hat is predictive of each echocardiographic parameter. Mul-
iple regression analysis revealed unique correlation proﬁles
f echocardiographic parameters between serum syndecan-
and plasma BNP concentrations; only EF was correlated
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Figure 1 Serum syndecan-4 concentration in patients with
heart failure and healthy subjects. The difference in Serum
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analysis. Fig. 5 shows event-free curve for high- and low-yndecan-4 concentration was compared between the two
roups by Mann—Whitney test. Statistical signiﬁcance was
eﬁned as 0.01.
ith both of them. LV mass index, LV end-diastolic vol-
me (LVEDV), and systolic left ventricular diameter (LVDs),
arameters of LV geometry, were correlated only with
erum syndecan-4 concentration, while early transmitral
ow velocity/early diastolic velocity of the mitral valve
nnulus (E/e′), right ventricular systolic pressure (RVSP),
nd left atrial volume index, parameters for blood ﬂow and
ressure, were mainly correlated with plasma BNP concen-
ration.
Simple regression analysis also demonstrated signiﬁcant
orrelation of syndecan-4 with EF, LV mass index, LVEDV, and
VDs (Figs. 2 and 3 and Table 3). These data suggest that
yndecan-4 represents a different aspect of cardiac function
rom BNP, MMP2, and TGF-1.
s
P
h
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Table 2 Biomarkers for prediction of echocardiographic paramet
Objective variable Multiple
correlation
coefﬁcient (R)
p Explanatory vari
Syndecan-4
Partial regressio
coefﬁcient (ˇ)
EF 0.708 0.001 −0.382
LV mass index 0.313 0.041 0.313
LVEDV 0.384 0.013 0.384
LVDs 0.548 0.001 0.548
e′ 0.331 0.022
E/e′ 0.450 0.001
RVSP 0.602 0.001
LA volume index 0.614 0.004
BNP, B-type natriuretic peptide; EF, ejection fraction; LV, left ventric
left ventricular diameter; RVSP, right ventricular systolic pressure; LA
velocity of the mitral valve annulus; MMP2, matrix metalloproteinase-2
were converted by logarithmic transformation.
Biomarkers (explanatory variables) used to predict each echocardiograp
regression analysis. Multiple correlation coefﬁcient (R) of each predic
that are predictive of echocardiographic parameters are shown. Tenasc
parameter in multiple regression analysis.R. Takahashi et al.
elationship among biomarkers
e next examined whether syndecan-4 correlates with
ther biomarkers. As shown in Table 4, serum syndecan-4
oncentration did not signiﬁcantly correlate with the con-
entrations of BNP, MMP2, TGF-1, and tenascin-C.
rognostic value of serum syndecan-4
oncentration for cardiac events
uring the 3-year follow-up, 10 patients were re-admitted
o the hospital due to worsening of heart failure and 5 of
hem subsequently died of heart failure. The ROC curves
f serum sybdecan-4 and plasma BNP concentration for
he prediction of cardiac death or re-hospitalization due
o heart failure are shown in Fig. 4. The area under the
urve (AUC) of serum syndecan-4 concentration for the pre-
iction of cardiac death or re-hospitalization due to heart
ailure was 0.706 (95% conﬁdence interval: 0.537—0.875,
< 0.05), while that of plasma BNP concentration was 0.763
95% conﬁdence interval: 0.601—0.912, p < 0.01). AUCs of
GF-, MMP2, and tenascin-C for the prediction of cardiac
eath or re-hospitalization due to heart failure were 0.418,
.639, and 0.618, respectively, and these values were not
igniﬁcant.
Since the value for (1− sensitivity)2 + (1− speciﬁcity)2
as minimal when the serum syndecan-4 concentration
as 18.4 ng/mL, we deﬁned this concentration as the opti-
al cut-off point discriminating cardiac events for furthererum syndecan-4 concentration by Kaplan—Meier analysis.
atients with serum syndecan-4 concentration >18.4 ng/mL
ad a signiﬁcantly lower event-free rate (p < 0.01, log-rank
est).
ers in multiple regression analysis.
ables
BNP MMP2 TGF-1
n p ˇ p ˇ p ˇ p
0.003 −0.481 0.001
0.041
0.013
0.001
0.331 0.022
0.450 0.001
0.602 0.001
0.424 0.004 0.316 0.029
ular; LVEDV, left ventricular end-diastolic volume; LVDs, systolic
, left atrial; E/e′, early transmitral ﬂow velocity/early diastolic
; TGF-1, transforming growth factor-beta 1. Data of biomarkers
hic parameter (objective variables) were determined by multiple
tive formula and partial regression coefﬁcient (ˇ) of biomarkers
in-C was not signiﬁcantly correlated with each echocardiographic
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Figure 2 Correlation of serum syndecan-4 and B-type natriuretic peptide (BNP) concentrations with ejection fraction (EF). Pear-
son’s correlation coefﬁcient of the concentration of serum syndecan-4 (A) and plasma BNP (B) with EF was calculated. Since the
distribution pattern of serum biomarker concentration did not match with normal distribution, data were converted by logarithmic
transformation and then statistical tests were performed.
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Figure 3 Correlation of serum syndecan-4 and plasma B-type natriuretic peptide (BNP) concentrations with left ventricular (LV)
mass index. Pearson’s correlation coefﬁcient of the concentration of serum syndecan-4 (A) and plasma BNP (B) with the LV mass
index was also calculated after logarithmic transformation. ns, not signiﬁcant.
Table 3 Correlation between biomarkers and echocardiographic parameters in simple regression analysis.
Syndecan-4 BNP MMP2 TGF-1 Tenascin-C
EF −0.599* −0.614* −0.224 0.018 −0.301*
LV mass index 0.315* 0.135 −0.084 0.187 0.102
LVEDV 0.380* 0.277 0.101 −0.109 −0.064
LVDs 0.583* 0.354* 0.127 −0.155 0.124
e′ −0.268* −0.035 −0.113 0.380* 0.189
E/e′ −0.132 −0.441* 0.191 −0.303* 0.083
RVSP 0.056 0.618* 0.381* −0.118 0.392
LA volume index 0.111 0.538* 0.479* −0.225 0.206
BNP, B-type natriuretic peptide; EF, ejection fraction; LV, left ventricular; LVEDV, left ventricular end-diastolic volume; LVDs, systolic
left ventricular diameter; RVSP, right ventricular systolic pressure; LA, left atrial; E/e′, early transmitral ﬂow velocity/early diastolic
velocity of the mitral valve annulus; MMP2, matrix metalloproteinase-2; TGF-1, transforming growth factor-beta 1.
* p < 0.05.
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Table 4 Correlation among biomarkers in simple regression analysis.
BNP MMP2 TGF-1 Tenascin-C
Syndecan-4 0.258 0.018 0.07 0.205
BNP 0.294* −0.054 0.652*
MMP2 −0.539* −0.033
TGF-1 *
BNP, B-type natriuretic peptide; MMP2, matrix metalloproteinase-2; TG
* p < 0.05.
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Figure 4 Predictive ability of serum syndecan-4 and plasma
B-type natriuretic peptide (BNP) concentration for heart failure
events. The receiver operating characteristic curve was created
to predict death and re-hospitalization caused by worsening
of heart failure based on serum syndecan-4 and plasma BNP
concentration. AUC, area under the curve.
1.0
Syndecan 4<18 4 ng/mL
0.8
ra
te
S d 4 18 4
- .
0 4
0.6
en
t-f
re
e
r yn ecan- > . ng/mL
0.2
.
E
ve
0 10 20 30 36
0
( th )
p<0.01
mon s
Figure 5 Kaplan—Meier event-free curves for serum
syndecan-4 concentrations. Event-free rate from death and
re-hospitalization caused by worsening of heart failure was
compared between high- and low-serum syndecan-4 concen-
trations by Kaplan—Meier analysis. Cut-off level of serum
syndecan-4 concentration (18.4 ng/mL) was determined by the
receiver operating curve. Statistical signiﬁcance of separation
between 2 groups was achieved by log-rank test at 36 months.
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iscussion
his study demonstrated that serum syndecan-4 con-
entration was signiﬁcantly increased in patients with
eart failure. In addition, serum syndecan-4 concentration
nversely correlated with EF and positively correlated with
eometrical parameters of LV hypertrophy and enlargement,
ncluding LV mass index, LVEDV, and LVDs. The increase in
erum syndecan-4 concentration was a predictor of cardiac
eath and re-hospitalization due to heart failure. This is
he ﬁrst report to demonstrate elevated serum syndecan-4
oncentration in patients with heart failure.
Heart failure results from complex architectural, cellu-
ar, and molecular changes involving necrosis, apoptosis, and
epair processes. Several humoral factors have been used
o monitor cardiac performance in the context of heart
ailure. Many biomarkers are now applied to estimate the
ardiac function in the failing heart [10]. At present, the
ost representative cardiac biomarker for heart failure is
onsidered to be BNP, which exerts a natriuretic effect as
ell as an anti-ﬁbrotic effect [11]. BNP is secreted mainly
rom the ventricle in response to myocardial stretch, i.e.
he elevation of the LV ﬁlling pressure [12]. BNP subse-
uently reduces hemodynamic overload in the failing heart
nd inhibits ﬁbrosis-mediated cardiac remodeling. Measur-
ng the plasma BNP level is useful to diagnose true heart
ailure in patients with dyspnea during their visit to the
mergency room [13]. It also can predict in-hospital and
ostdischarge survival in heart failure patients [14].
Syndecan-4 has been reported to promote wound heal-
ng and angiogenesis in granulation tissue after skin injury
3]. In the rat experimental infarction model, mRNA lev-
ls and protein amount of syndecan-4 were increased in the
oninfarcted LV tissue one week after myocardial infarction,
uggesting that syndecan-4 has the potential to promote the
ypertrophic response in the noninfarcted myocardium [15].
ojima et al. reported an elevated serum syndecan-4 level
ith a peak value at 2 weeks after myocardial infarction [5],
hich corresponds to the repair phase. They also demon-
trated abundant production of syndecan-4 protein in the
epair region, but not the undamaged or ﬁbrous scar region
fter myocardial infarction [5]. Thus, syndecan-4 may rep-
esent an aspect of heart failure different from BNP. In fact,
ur data show a signiﬁcant correlation of serum syndecan-
concentration with LV geometrical parameters (LV massndex, LVEDV, and LVDs), while BNP was signiﬁcantly cor-
elated with pressure-related parameters (E/e′, RVSP, and
A volume, a barometer of LV ﬁlling pressure) [16]. Since
F is the ratio between stroke volume (a pressure-related
hysiological measurement) and EDV (a geometrical mea-
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surement), it is not surprising that both syndecan-4 and BNP
were correlated with EF. Moreover, no correlation was found
between syndecan-4 and BNP and other biomarkers, sug-
gesting that syndecan-4 is a novel independent biomarker
from BNP, MMP2, TGF-1, and tenascin-C. Our data thus sug-
gest that serum syndecan-4 concentration may represent a
biomarker speciﬁcally for LV geometrical remodeling rather
than hemodynamic changes in the failing heart.
We next examined whether serum syndecan-4 concen-
tration has predictive power of cardiac events. During
the 3-year follow-up, 10 patients (22%) were re-admitted
to the hospital, and 5 of them (11%) died of heart fail-
ure. The AUC for the prediction of cardiac death and
re-hospitalization due to heart failure, based on serum
syndecan-4 concentration at the ﬁrst hospitalization (0.706,
p < 0.05), was second to that based on plasma BNP concen-
tration (0.763, p < 0.01). However, since the 95% conﬁdence
interval of serum syndecan-4 (0.537—0.875) overlapped
with that of plasma BNP (0.601—0.912), predictive power
of cardiac events of these biomarkers was not statisti-
cally different. AUCs based on concentrations of TGF-1,
MMP2, and tenascin-C did not signiﬁcantly predict death
and re-hospitalization due to heart failure. In addition,
Kaplan—Meier analysis demonstrated that patients with
serum syndecan-4 concentration >18.4 ng/mL had a signiﬁ-
cantly lower cardiac event-free rate.
Tenascin-C is a ubiquitously expressed heparan sulfate
proteoglycan that is structurally related to syndecan-4. A
recent study has reported that tenascin-C is increased in
patients with heart failure and idiopathic dilated cardiomy-
opathy [17]. Tenascin-C and syndecan-4 are transiently
up-regulated during tissue repair and wound healing in vari-
ous tissues. Thus, this study also measured serum tenascin-C
concentration in the patient population. However, tenascin-
C concentration had a weak inverse correlation only with
EF (Table 3) and there was no signiﬁcant correlation
between levels of these two proteoglycans (Table 4). Among
syndecan-4, TGF-1, MMP2, and tenascin-C, which are
involved in ECM turnover, only syndecan-4 could predict car-
diac events, suggesting a key role of syndecan-4 in cardiac
remodeling in the context of ECM metabolism.
Approximately 50% of patients with heart failure have
preserved EF [18]. The plasma BNP level is reportedly
higher in those patients with reduced EF than with
preserved EF [19]. We also found signiﬁcantly higher
plasma BNP concentration in patients with EF of less
than 55% (688.0± 358.7 pg/mL) than with EF more than
55% (164.2± 147.9 pg/mL, p < 0.05). In contrast, serum
syndecan-4 concentration in each group was not signiﬁcantly
different between patients with reduced and preserved EF
(25.9± 12.8 ng/mL vs. 20.7± 12.9 ng/mL, ns); serum con-
centrations of TGF-1, MMP2, and tenascin-C were also not
signiﬁcantly different between these two types of heart fail-
ure. These data suggest no differences in ECM metabolism
in patients with reduced or preserved EF heart failure.Study limitations
Although our study indicated a signiﬁcant correlation
between serum syndecan-4 concentration, other humoral
factors, and echocardiographic parameters, the relatively331
mall patient population limits the statistical power for
etecting the relationships between other parameters.
hus, further investigation with a larger patient popula-
ion would be of beneﬁt. In addition, investigation of the
ource of syndecan-4 production would greatly advance our
nderstanding of the pathophysiology of heart failure and
emodeling.
onclusions
erum syndecan-4 concentration is increased in patients
ith chronic heart failure, inversely correlated with EF, and
ositively correlated with LV geometric parameters. Fur-
hermore, serum syndecan-4 concentration could predict
ardiac death and re-hospitalization due to heart failure.
iven that it is a co-receptor of growth factor receptors for
broblast growth factor-2, hepatocyte growth factor, and
latelet derived growth factor, syndecan-4 may be useful as
biomarker for diagnosis of the LV remodeling process in
atients with heart failure.
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